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Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issue of
Cancer Cell, Junttila et al. show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K
complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which
explains why trastuzumab is ineffective in some tumors.Approximately 20% of breast tumors
possess the 17q11-24 ERBB2-containing
amplicon and show a dramatic overex-
pression of ErbB2 (reviewed in Hynes
andLane, 2005). Trastuzumab is ahuman-
ized antibody targeting ErbB2 and bene-
fits patients with ErbB2-overexpressing
breast cancer, particularly when used in
the adjuvant setting. However, not all
patients whose tumors overexpress
ErbB2 respond to trastuzumab treatment.
In spite of a vast amount of research and
clinical data, there are still important unre-
solved questions related to trastuzumab’s
mechanism of action and to predicting
patient response.
ErbB2 is amember of the ErbB receptor
tyrosine kinase (RTK) family, which also
includes EGFR, ErbB3, and ErbB4. Under
normal physiological conditions, activa-
tion of these receptors is controlled by
spatial and temporal expression of their
ligands. Ligand binding induces formation
of ErbB receptor homo- and hetero-
dimers, resulting in activation of the cyto-
plasmic kinase domain, which promotes
phosphorylation of specific tyrosine resi-
dues (P-Y) and stimulates intracellular
signaling cascades (Hynes and Lane,
2005). ErbB2 is ligandless and functions
as a coreceptor with other ligand-bound
ErbBs. Of the four ErbB receptors,
ErbB3 is best suited to activate the
PI3K/AKT pathway due to having multiple
p85/p110a binding sites. ErbB3 binds
heregulins (HRG) but has impaired kinase
activity and only signals as a complex with
another ErbB, preferably ErbB2 (Hynes
and Lane, 2005). In breast cancer cells,
overexpressed ErbB2 is highly phosphor-
ylated in the absence of ligands and the
PI3K/AKT pathway is constitutively ac-
tive. However, ErbB2 does not functionalone: it requires ErbB3 as a link to the
PI3K/AKT pathway (Holbro et al., 2003)
(Figure 1A, middle). Previous studies
have revealed how ligand binding regu-
lates ErbB receptor dimerization and
where trastuzumab binds ErbB2 (re-
viewed in Leahy, 2008).
Junttila and colleagues now show that
trastuzumab causes destabilization of
ligand-independent constitutive ErbB2/
ErbB3 complexes, uncoupling of ErbB3
from ErbB2, and blockade of downstream
PI3K/AKTsignaling in ErbB2-overexpress-
ing tumor cells (Junttila et al., 2009). This
effect of trastuzumab may be one impor-
tant mechanism underlying its clinical
activity, however, as discussed in their
paper other mechanisms are also likely
to be relevant in cancer patients. Further-
more, this studyshows that therearediffer-
ences between ligand-independent and
ligand-induced ErbB2/ErbB3 complexes.
Despite the fact that ErbB2-overexpress-
ing tumor cells have high levels of P-Y
ErbB3 and high PI3K/AKT activity, HRG
treatment causes a further increase in
both. Moreover, HRG prevents trastuzu-
mab from disrupting ErbB2/ErbB3 com-
plexes. However, pertuzumab, an anti-
body that binds ErbB20s dimerization arm
(reviewed in Leahy, 2008) does prevent
HRG-induced ErbB2/ErbB3 complex
formation (Figure 1B, right side). Taken to-
gether, the results show that the ligand-in-
dependent, trastuzumab-sensitive ErbB2/
ErbB3 complex is structurally distinct
from HRG-induced ErbB2/ErbB3 hetero-
dimers. It will be interesting to uncover if
there are differences in the proteins and
intracellular pathways downstream of
these two ErbB2/ErbB3 complexes.
Additional important results presented
in this study are related to the PI3K/AKTCancer Cpathway. Activating mutations in PIK3CA,
the gene encoding the p110a catalytic
subunit of PI3K, are relatively common in
breast cancer. Furthermore, decreased
expression of PTEN, the phosphatase
that dephosphorylates PIP3, is often
found in breast cancers (Stemke-Hale
et al., 2008). Previous analyses of trastu-
zumab-treated ErbB2 overexpressing
breast cancer patients suggest that low
PTEN levels or PIK3CA activating muta-
tions are markers for poor response to
trastuzumab (Berns et al., 2007; Nagata
et al., 2004).
The work of Junttila and colleagues not
only impinges on these findings, but also
shows how resistance can be overcome.
They demonstrate that ErbB2-overex-
pressing breast tumor lines with low
PTEN or activating PIK3CA mutations do
not respond to trastuzumab; AKT activity
and tumor cell proliferation remain high.
Interestingly, in all tumor cells, irrespec-
tive of the presence or absence of PI3K
pathway mutations, trastuzumab dis-
rupts ligand-independent ErbB2/ErbB3
complexes, leading to a loss of p85/
p110a from ErbB3. However, in trastuzu-
mab-treated cells with mutant PI3K or
low PTEN, AKT activity remains high
(Figure 1A, left side). These results sug-
gest that, despite uncoupling p85/p110a
from the ErbB2/ErbB3 complex, mutant
PI3K remains localized at the membrane,
perhaps using its Ras-binding domain,
where it continues to catalyze PIP3
formation, AKT activation, and tumor cell
proliferation.
Based on the importance of the PI3K
pathway in human cancers, much effort
is going into the development of
PI3K/AKT pathway inhibitors (Garcia-




Figure 1. Targeting ErbB2/ErbB3/PI3K
(A) Junttila et al. (2009) provide evidence that a ligand-independent, constitutive complex of ErbB2/ErbB3/
PI3K functions as an oncogenic unit in ErbB2-overexpressing breast cancer cells (middle). Trastuzumab
disrupts the ErbB2/ErbB3 interaction and decreases ErbB3 phosphorylation, which in turn uncouples
PI3K from ErbB3 and leads to a block of AKT phosphorylation that correlates with inhibition of proliferation
of tumor cells (left side). Activating mutations of the PI3K catalytic subunit (e.g., E542K, E545K, and
H1047R) result in constitutive active PI3K independent of its association with ErbB3, which maintains
AKT signaling even in the presence of trastuzumab and thereby renders the cells resistant to trastuzumab
(left side). GDC-0941, a selective PI3K inhibitor, synergizes with trastuzumab in inducing not only a prolif-
erative block but also apoptotic cell death of ErbB2-overexpressing cells with wild-type PI3K (right side).
Moreover, GDC-0941 inhibits the growth and survival of trastuzumab-insensitive PI3K mutant breast
tumor cell lines (right side).
(B) HRG-binding induces a major conformational change in ErbB3 enabling its interaction with ErbB2
through its domain II dimerization arm (left side). Pertuzumab, an antibody that binds ErbB2’s dimerization
arm disrupts ligand-induced heterodimer formation and downstream signaling (right side) (reviewed in
Leahy, 2008). EGFR/ErbB2 TKIs like lapatinib are able efficiently inhibit HRG-induced signaling, whereas
trastuzumab binding to domain IV of ErbB2 has no effect on signaling and proliferation (left side) (reviewed
in Hynes and Lane, 2005). Lapatinib also decreases downstream signaling pathway activity and blocks
proliferation of ErbB2-overexpressing tumor cells (middle) (reviewed in Hynes and Lane, 2005). However,
activating PI3K mutations confer resistance to lapatinib and cells maintain PI3K/AKT signaling (middle)
(Eichhorn et al., 2008).354 Cancer Cell 15, May 5, 2009 ª2009 Elsevier Inc.is a PI3K inhibitor with selective activity
toward the class 1A isoforms p110a,
p110b, and p110d. Junttila and col-
leagues show that even in ErbB2-over-
expressing tumor cells with no PI3K
pathway mutations, the addition of GDC-
0941 to trastuzumab has a synergistic
effect on blockade of AKT activity. Fur-
thermore, compared to individual treat-
ment with GDC-0941 or trastuzumab,
combination treatment has stronger
in vitro and in vivo antiproliferative activity
and causes an increase in cell death.
Importantly, in trastuzumab-resistant
tumor cells, GDC-0941 decreases AKT
activity, lowers in vitro tumor cell prolifer-
ation, and blocks xenograft outgrowth
(Figure 1A, right side).
Several other PI3K inhibitors are in clin-
ical development, many of these block
mTOR in addition to the PI3K class 1A
isoforms (Garcia-Echeverria and Sellers,
2008). Since PI3K is crucial for correct
insulin signaling, hyperglycemia as a
potential serious side-effect of its inhibi-
tion is a major concern in developing
PI3K inhibitors. Although there is no
formal published report yet, preliminary
reports on several of these compounds
did not reveal any serious side effects.
All PI3K inhibitors are still in early develop-
mental phases so it is too early to say
whether they will become useful for breast
cancer treatment.
The results presented by Sliwkowsi and
colleagues strongly suggest that it should
be possible to overcome trastuzumab
resistance in patients with PI3K pathway
mutations. What about lapatinib, a dual
EGFR/ErbB2 kinase inhibitor which was
FDA approved for treatment of ErbB2-
overexpressing breast cancer based on
its effectiveness in patients who failed on
trastuzumab (Geyer et al., 2006)? Lapati-
nib can block most combinations of
ErbB dimers, and it is likely that these
characteristics contributed to its efficacy
in trastuzumab-resistant tumors (Fig-
ure 1B, left side). An important question
is whether lapatinib will work in tumors
with PI3K pathway mutations. There are
not many clinical reports regarding this
issue, the PIK3CA mutation status was
not examined in most clinical studies.
However, low PTEN levels did not
preclude lapatinib response (Johnston
et al., 2008). On the other hand, introduc-
tion of active PI3K mutants rendered the
tumor cells resistant to lapatinib in a
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by NVP-BEZ235, a dual PI3K-mTOR
inhibitor, treatment (Eichhorn et al., 2008)
(Figure 1B, middle). Given the frequency
of mutations in this pathway, PI3K
appears to be an excellent target for
therapy. The oncology field eagerly awaits
further information on the clinical useful-
ness of PI3K inhibitors.
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TAMs and their secreted TNFa. And
once again, this potentiates the tumor
phenotype, this time promoting metas-
tasis. However, the newly discovered
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(Zhou et al., 2004). As with b-catenin,
TNFa-mediated Snail stabilization occurs
through inhibition of GSK3b-dependent
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